Base de dados : LILACS
Pesquisa : D12.776.395.550.560 [Categoria DeCS]
Referências encontradas : 8 [refinar]
Mostrando: 1 .. 8   no formato [Detalhado]

página 1 de 1

  1 / 8 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1114915
Autor: Samar-Romani, María Elena; Ávila-Uliarte, Rodolfo Esteban; García-Esst, Pedro Emilio; Fonseca-Acosta, Ismael Bernardo; Fernández-Calderón, Javier Elías.
Título: Expresión de Ki67 y MUC-1 en el adenocarcinoma no especificado de otra manera (NOS) de glándulas salivales: su valor pronóstico / Ki67 and MUC-1 expression in adenocarcinoma not otherwise specified (NOS) of salivary glands: prognostic value
Fonte: Int. j. odontostomatol. (Print);14(3):407-416, 2020. tab, graf.
Idioma: es.
Projeto: Universidad Nacional de Córdoba.
Resumo: El adenocarcinoma NOS (no especificado de otra manera) es un tumor salival sin patrón especial poco mencionado en la literatura; su diagnóstico es un desafío porque estructuralmente no se identifica con otros carcinomas salivales más definidos. Por otro lado, Ki67 es un marcador de proliferación celular que brinda información pronóstica de las neoplasias. En cuanto a la mucina humana transmembrana MUC-1 se sobre-expresa en las neoplasias malignas perdiendo su localización exclusivamente apical. Presentamos dos casos de adenocarcinoma NOS diagnosticados con H/E y correlacionamos la expresión de Ki67 y la localización y sobreexpresión de MUC-1 con su grado histológico y pronóstico. Cortes histológicos de dos adenocarcinomas NOS de parótida en mujeres de 62 y 63 años respectivamente se colorearon con H/E e inmunomarcaron para Ki67 y MUC-1. En ambos tumores predominaban estructuras ductales, algunas quísticas, cordones celulares ramificados e islotes sólidos. Las formaciones glandulares presentaban células claras y algunas de aspecto oncocítico. Había importante atipia celular, comedonecrosis, invasión perineural, áreas hemorrágicas y compromiso de los márgenes quirúrgicos. La marcación nuclear con Ki67 fue importante; MUC-1 presentó una fuerte coloración en membranas y citoplasmas. Las dos lesiones se diagnosticaron como de alto grado de malignidad. Nuestros resultados demuestran que existe una importante proliferación marcada con Ki67 y una sobre-expresión de MUC-1 asociadas a atipia celular, infiltración perineural, necrosis y compromiso de márgenes quirúrgicos, factores asociados a un peor pronóstico. El reconocimiento de este tumor es trascendente para médicos y odontólogos ya que por la ausencia de rasgos distintivos que sí presentan otros carcinomas más específicos es fundamental el diagnóstico de exclusión.

Adenocarcinoma NOS (not otherwise specified) is a no special pattern salivary tumor briefly mentioned in the literature; its diagnosis is a challenge because structurally it is not identified with other more definite salivary carcinomas. On the other hand, Ki67 is a marker of cellular proliferation that provides prognostic information of neoplasms. As for human transmembrane mucin, MUC-1 is overexpressed in malignant neoplasms, losing their exclusively apical location. We present two cases of adenocarcinoma NOS diagnosed with H/E and correlate the expression of Ki67 and the location and over-expression of MUC-1 with its histological grade and prognosis. Histological sections of two NOS adenocarcinomas of parotid in women of 62 and 63 ages respectively were stained with H/E and immunolabelled for Ki67 and MUC-1. Both are predominated by ductal structures, some cystic, branched cell cords and solid islets. The glandular formations presented clear cells and some of oncocytic appearance. There was important cellular atypia, comedonecrosis, perineural growth, haemorrhagic areas and compromise of surgical margins. Nuclear marking with Ki67 was important; MUC-1 presented a strong staining in membranes and cytoplasms. They were diagnosed as high-grade malignancy. Our results show that there is an important proliferation marked with Ki67 and overexpression of MUC-1 associated with cellular atypia, perineural growth, necrosis and compromise of surgical margins, factorsassociated with a poor prognosis. The recognition of this tumor is transcendent for physicians and dentists since, due to the absence of distinctive features that other more specific carcinomas present, the diagnosis of exclusion is essential.
Descritores: Neoplasias Parotídeas/diagnóstico
Neoplasias Parotídeas/metabolismo
Neoplasias Parotídeas/patologia
Adenocarcinoma/metabolismo
Adenocarcinoma/patologia
-Prognóstico
Neoplasias das Glândulas Salivares
Imuno-Histoquímica
Adenocarcinoma/diagnóstico
Biomarcadores Tumorais
Mucina-1/metabolismo
Antígeno Ki-67/metabolismo
Proliferação de Células
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  2 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1088932
Autor: Araújo, P. B; Campinho, D. S. P; Mendonça, F. S; Evêncio Neto, J.
Título: Dosagem sérica do marcador tumoral CA 15. 3 em cadelas portadoras de neoplasias mamárias pelo método de eletroquimioluminescência / Serum dosage of the tumor marker Ca 15. 3 in bitches presenting mammary neoplasia with the chemiluminescence method
Fonte: Arq. bras. med. vet. zootec. (Online);72(1):290-294, Jan.-Feb. 2020. tab.
Idioma: pt.
Resumo: The objective of the present study was to analyze the serum levels of the tumor marker Ca15.3 in healthy bitches and those with mammary neoplasms, correlating results with tumor type, clinical staging, time until presentation, and presence of ulceration and vascularization. For the study, 30 bitches with mammary tumors and 30 healthy bitches (control group) were selected. Histopathology was performed for identification of tumor type, and blood was collected for measurement of serum concentration of the marker via the chemiluminescence method using a commercial kit. A higher frequency of malignant neoplasms was observed (76.7%), with a higher quantity of carcinoma in mixed tumor (26.7%). Regarding serum concentration of the marker Ca15.3, there was no difference in serum values when comparing the means from bitches with neoplasia and healthy bitches, nor when comparing the other characteristics. The majority of results for serum concentration of Ca15.3, whether in bitches with neoplasia or in healthy bitches, was zero. It is concluded that the measurement of the marker Ca15.3 using the chemiluminescence method and commercial kits for humans did not offer significant results that would make this method or this marker a useful tool for patient monitoring and evaluation of the prognosis of bitches with mammary neoplasms.(AU)
Descritores: Biomarcadores Tumorais/sangue
Neoplasias Mamárias Animais
Mucina-1/administração & dosagem
Luminescência
Eletroquimioterapia/veterinária
Limites: Animais
Feminino
Cães
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  3 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-976507
Autor: Roberto, Gabriela B; Ziliotto, Liane; Seki, Meire Christina.
Título: Avaliação comparativa de dosagem do marcador tumoral CA 15-3 em cadelas hígidas ou com neoplasia mamária / Comparative evaluation of tumor marker CA 15-3 dosage in dogs, healthy or with breast cancer
Fonte: Pesqui. vet. bras = Braz. j. vet. res;38(9):1800-1807, set. 2018. tab, graf.
Idioma: pt.
Resumo: O antígeno CA 15-3 é uma proteína presente no soro utilizado no acompanhamento de mulheres com câncer de mama, essencialmente na detecção de metástases. Os objetivos deste estudo foram avaliar a efetividade e a viabilidade da utilização do marcador tumoral CA 15-3 em cadelas, comparando-se os valores do marcador entre cadelas sem e com neoplasia mamária, avaliando-se alterações nos valores do marcador após a mastectomia, e suas correlações entre o tipo histológico. Foi realizada a quantificação sérica do marcador tumoral CA 15-3 (teste de eletroquimioluminescência), em vinte cadelas hígidas (grupo controle) e vinte cadelas com neoplasia mamária (grupo teste). Os animais com neoplasia tiveram a dosagem do marcador realizada antes e 10 dias após a mastectomia. Ainda, foi realiza a citologia vaginal no momento da mastectomia e foram estabelecidos três grupos de acordo com a fase estral de cada cadela, Diestro, Proestro e Anestro. As massas tumorais foram encaminhadas para exame histopatológico. A avaliação dos dados de citologia vaginal entre os grupos Diestro, Proestro e Anestro pelo teste de ANOVA não demonstrou diferença estatística significativa entre os valores encontrados. E na análise para a comparação dos valores do marcador tumoral com os tipos histológicos de neoplasias, divididas em dois grupos, benignas e malignas, utilizando o teste de Mann-Whitney Rank Sum Test, o teste não demonstrou diferença estatística significativa visto que p>0,05. Os valores encontrados do marcador no grupo controle foram uma média de 0,19+0,39 U/mL, no grupo pré-mastectomia 1,56+0,39 U/mL e pós-mastectomia 0,66+0,27 U/mL. Em análise estatística com a comparação de grupo pré e pós-mastectomia, e do grupo controle com o grupo pré e pós-mastectomia observou-se significância com p< 0,005. Assim, observou-se diferença nos valores do marcador antes e depois da remoção cirúrgica da neoplasia, sugerindo seu possível uso como controle de crescimento tumoral pós-mastectomia individual. Porém há muita variação dos resultados nos diferentes métodos existentes, e não há ainda um padrão dos valores de referência para cada método, sendo necessários mais estudos sobre o uso dos marcadores.(AU)

The CA 15-3 antigen is a protein present in the serum, used to monitor women with breast cancer, mainly in metastatic disease detection. The objective of this study was to evaluate the effectiveness and feasibility of the CA 15-3 tumor marker in dogs, comparing the marker values between dogs with or without breast cancer, to estimate changes in marker values after mastectomy, and their correlation between the histological types. Serum quantification of the tumor marker CA 15-3 (electrochemiluminescence test) was performed in twenty healthy bitches and twenty others with mammary neoplasia. Bitches with cancer had the content of the tracer performed before and 10 days after mastectomy. The vaginal cytology was performed at the moment of the mastectomy, dividing the animals into three different groups (diestrus, proestrus and anestrus). All the mammary tumors were examined histopathologically. The evaluation of the vaginal cytology data of the groups Diestro, Proestro and Anestro by the ANOVA test did not show a statistically significant difference between the values ​​found. In the analysis histological types of tumor marker values of neoplasms, divided into two groups, benign and malignant, using the Mann-Whitney Rank Sum Test, there was no statistical significant difference at p>0.05. The values of the marker in the control group had an average of 0.19+0.39 U/mL, of the pre-mastectomy group 1.56+0.39 U/mL, and of the post-mastectomy group 0.66+0.27 U/mL. The statistic was performed comparing groups pre- and post-mastectomy, and the control group with group pre- and post-mastectomy with a statistical significance p< 0.005 in both tests. There was a difference of marker values ​​before and after surgical removal of the neoplasia, suggesting its possible use in post-mastectomy tumor control. But exist variation of results with the different existing methods, and there will be still a standard reference value for each method.(AU)
Descritores: Neoplasias da Mama/veterinária
Biomarcadores Tumorais/análise
Cães/anormalidades
-Mucina-1
Eletroquimioterapia
Limites: Animais
Feminino
Cães
Responsável: BR68.1 - Biblioteca Virginie Buff D'Ápice


  4 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-752429
Autor: PONCE-BRAVO, Santa; LEDESMA-MONTES, Constantino; GARCÉS-ORTÍZ, Maricela.
Título: MUC-1 expression in pleomorphic adenomas using two human milk fat globule protein membrane antibodies (HMFG-1 and HMFG-2)
Fonte: J. appl. oral sci;23(3):265-271, May-Jun/2015. graf.
Idioma: en.
Resumo: Pleomorphic adenoma (PA) is the most common salivary gland tumor and its microscopic features and histogenesis are a matter of debate. Human milk fat globule protein membrane (HMFG) monoclonal antibodies (MoAbs) comprise a set of antibodies against the mucin 1 (MUC-1) protein detected in several salivary gland tumors. Objective The aim of this study was to assess the immunoexpression of the PA neoplastic cells to MUC-1 protein using HMFG-1 and HMFG-2 MoAbs, contrasting these results with those from normal salivary gland tissue. Material and Methods Immunohistochemical detection of MUC-1 protein using HMFG-1 and HMFG-2 MoAbs was made in 5 mm thick, paraffin embedded slides, and the avidin-biotin method was used. Results Positivity to HMFG-1 and HMFG-2 MoAbs was found in ductal, squamous metaplastic and neoplastic myoepithelial cells, keratin pearls and intraductal mucous material. Two kinds of myoepithelial cells were identified: classic myoepithelial cells around ducts were negative to both MoAbs, and modified myoepithelial cells were positive to both MoAbs. This last cellular group of the analyzed tumors showed similar MUC-1 immunoexpression to ductal epithelial cells using both HMFG antibodies. Intraductal mucous secretion was also HMFG-1 and HMFG-2 positive. Conclusions Our results showed there are two kinds of myoepithelial cells in PA. The first cellular group is represented by the different kinds of neoplastic myoepithelial cells and is HMFG-positive. The second one is HMFG-negative and represented by the neoplastic myoepithelial cells located around the ducts. .
Descritores: Anticorpos Monoclonais
Adenoma Pleomorfo/química
Glicolipídeos
Glicoproteínas
Proteínas de Membrana
Mucina-1/análise
Neoplasias das Glândulas Salivares/química
-Adenoma Pleomorfo/patologia
Biomarcadores Tumorais/análise
Estudos de Casos e Controles
Imuno-Histoquímica
Inclusão em Parafina
Valores de Referência
Neoplasias das Glândulas Salivares/patologia
Glândulas Salivares/química
Glândulas Salivares
Coloração e Rotulagem/métodos
Limites: Humanos
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  5 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-701731
Autor: Morales M, Erik; Rojas R, Armando; Monasterio A, Valeria; González B, Ileana; Figueroa C, Ingrid; Manques M, Belamiro; Romero E, Jaqueline; Llanos L, Jorge; Valdés M, Eliana; Cofré L, Cecilia.
Título: Lesiones gástricas en pacientes infectados con Helicobacter pylori: expresión de RAGE (receptor de productos de glicosilización avanzada) y otros inmunomarcadores / Expression of RAGE in Helicobacter pylori infested gastric biopsies
Fonte: Rev. méd. Chile;141(10):1240-1248, oct. 2013. ilus, graf.
Idioma: es.
Resumo: Background: Inflammation is a common phenomenon present in gastric mucosa of patients infected with H. pylori. Activation of the RAGE/multiligand axis is thought to be a relevant factor in cancer-mediated inflammation. RAGE is a membrane receptor, belonging to the immunoglobulin family, and the over-expression of RAGE has been associated with increased invasiveness and metastasis generation in different types of cancer, including gastric cancer. Furthermore recent experiences show that the use of its soluble form (sRAGE) or silencing of the gene coding for this receptor could provide therapeutic benefits in cancer. Aim: To evaluate the immunohistochemical expression of RAGE, MUC-1, β-Catenin free and phosphorylated, Cyclin-D1 and GSK3 in gastric biopsy specimens infected with H. pylori. Material and Methods: Immunohistochemical analysis was carried out in gastric biopsies from 138 patients: 55 with inflammatory injury (no atrophic gastritis), 42 with pre-cancerous conditions (atrophy or intestinal metaplasia) and 41 with dysplastic lesions or in situ adenocarcinoma. Results: There was a high rate of positive RAGE expression in the three groups of biopsies. Biopsies with dysplasia or in situ carcinoma had a significantly higher percentage of RAGE expression than the other groups of biopsies. Conclusions: The increased RAGE expression reported in both dysplasia and incipient cancer support the role of the multiligand/RAGE axis in gastric carcinogenesis.
Descritores: Mucosa Gástrica/química
Helicobacter pylori
Lesões Pré-Cancerosas/química
Receptores Imunológicos/análise
Neoplasias Gástricas/química
-Biópsia
Biomarcadores/análise
Ciclina D1/análise
Mucosa Gástrica/microbiologia
/análise
GLYCOGEN SYNTHASE KINASE ABATTOIRS/análise
Infecções por Helicobacter/metabolismo
Imuno-Histoquímica
Mucina-1/análise
beta Catenina/análise
Limites: Adulto
Idoso
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: CL1.1 - Biblioteca Central


  6 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-672981
Autor: Gokhan Ocak, GA; Yildirim, G; Elpek, GO.
Título: Hepatocyte antigen expression in subtypes of intestinal metaplasia of the stomach / Expresión del antígeno del hepatocito en los subtipos de metaplasia intestinal del estómago
Fonte: West Indian med. j;61(7):659-664, Oct. 2012. ilus, tab.
Idioma: en.
Resumo: OBJECTIVE: Recently, hepatocyte antigen (Hep) was introduced as a sensitive and reliable marker of intestinal metaplasia (IM). However, the distribution of Hep expression in subtypes of IM was not described. METHODS: We examined the expression of Hep in 58 cases of chronic gastritis associated with IM by immunohistochemical staining. Cases were classified as: 19 of IM Type I (complete) cases, 16 cases of IM Type II (incomplete) and 23 cases of IM Type III (incomplete). The distribution of Hep expression was classified into four groups according to the intensity of Hep expressing metaplastic cells: negative, low, moderate and high. We also compared expression of Hep with that of MUC-1, MUC-2 and MUC-5AC. RESULTS: Hep expression showed granular cytoplasmic staining and was specifically identified in columnar cells, but not in goblet cells. There was no significant difference between Hep expression and subtypes of IM (p > 0.005). However, the difference between the distribution of Hep expression among three subtypes of IM was significant (p < 0.001). No relationship was observed among the expression of Hep, MUC-1, MUC-2 and MUC-5AC. CONCLUSION: Results of the present study revealed that the distribution of Hep expression is high in the majority of the complete type (Type I) IM cases, moderate in the majority of the incomplete Type II IM cases and low in all of the incomplete Type III IM cases and suggest that besides its role as a sensitive marker in IM, the evaluation of the distribution of Hep expression might be useful in the classification of IM.

OBJETIVO: El antígeno del hepatocito (Hep) se introdujo recientemente como un marcador sensible y confiable de la metaplasia intestinal (MI). Sin embargo, no se describe la distribución de la expresión de Hep en los subtipos de MI. MÉTODOS: Se examinó la expresión de Hep en 58 casos de gastritis crónica asociados con MI mediante tinción inmunohistoquímica. Los casos fueron clasificados como: 19 casos de tipo MI (completo), 16 casos de tipo MI II (incompleto), y 23 casos de tipo MI III (incompleto). La distribución de la expresión del Hep se clasificó en cuatro grupos según la intensidad de Hep, que expresa las células metaplásticas: negativa, baja, moderada y alta. También se comparó la expresión de Hep con la de MUC-1, MUC-2 y MUC-5AC. RESULTADOS: La expresión de Hep mostró tinción citoplasmática granular, específicamente identificada en las células columnares, pero no en las células caliciformes. No hubo ninguna diferencia significativa entre la expresión de Hep y los subtipos de MI (p > 0.005). Sin embargo, la diferencia entre la distribución de la expresión del Hep entre tres subtipos de MI fue significativa (p < 0.001). No se observó relación alguna entre la expresión de Hep, MUC-1, MUC-2 y MUC-5AC. CONCLUSIÓN: Los resultados del presente estudio revelaron que la distribución de la expresión de Hep es alta en la mayoría de los casos MI de tipo completo (tipo I), moderada en la mayoría de los casos MI de tipo II, y baja en todos los casos MI de tipo III incompleto. Los resultados sugieren que además de su papel como marcador sensible en MI, la evaluación de la distribución de expresión del Hep podría ser útil en la clasificación de MI.
Descritores: Adenocarcinoma/metabolismo
Gastrite/metabolismo
Hepatócitos/imunologia
Lesões Pré-Cancerosas/metabolismo
Neoplasias Gástricas/metabolismo
-Adenocarcinoma/classificação
Adenocarcinoma/patologia
Mucosa Gástrica/imunologia
Mucosa Gástrica/patologia
Gastrite/patologia
Imuno-Histoquímica
Metaplasia/imunologia
/metabolismo
MUCIN ABDOMENAC/metabolismo
Mucina-1/metabolismo
/metabolismo
MUCIN-TEMEFOS/metabolismo
Lesões Pré-Cancerosas/imunologia
Lesões Pré-Cancerosas/patologia
Neoplasias Gástricas/imunologia
Neoplasias Gástricas/patologia
Biomarcadores Tumorais/metabolismo
Limites: Adulto
Idoso
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  7 / 8 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-656345
Autor: López C., Nayara; Ramón G., Natividad; Sánchez M., José Ignacio; de Santiago G., Javier.
Título: Metástasis óseas múltiples de cáncer de mama: papel del CA 15.3 y respuesta a la hormonoterapia / Bone metastasis of breast carcinoma: role of tumoral marker CA 15.3 and hormonal therapy response
Fonte: Rev. chil. obstet. ginecol;77(4):291-295, 2012. ilus.
Idioma: es.
Resumo: Las metástasis óseas suponen el 65-75 por ciento de casos de cáncer de mama avanzado. Los marcadores tumorales (CA 15.3, CEA) son útiles en el seguimiento de las pacientes y en la valoración de la respuesta al tratamiento. En el cáncer de mama metastásico de bajo grado, el tratamiento hormonal es la opción terapéutica más acertada debido a la baja toxicidad y alta probabilidad de respuesta generalmente de larga duración a la que se asocia. Se presenta el caso de una paciente con cáncer de mama tratado con cirugía, quimioterapia y radioterapia, asintomática durante el seguimiento y en la que metástasis óseas múltiples son detectadas a partir de una elevación del marcador CA 15.3. La hormonoterapia es el tratamiento pautado inicialmente con buena respuesta y tolerancia. Dicho tratamiento logra estabilizar las lesiones óseas durante 7 años y es precisamente al suspenderlo cuando aparecen nuevas lesiones también a nivel óseo detectadas de nuevo ante un incremento del marcador CA 15.3. La terapia hormonal pautada de nuevo vuelve a conseguir estabilizar las lesiones.

Bone metastases are involved in a 65-75 percent of advanced metastatic breast cancer cases. Tumoral markers (CEA, CA 15.3) are useful in the follow-up and evaluation of response to treatment. Hormonal therapy is the optimal treatment option in low grade metastatic breast cancer due to low toxicity and general long term good response. We present a breast cancer case treated with surgery, chemotherapy and radiotherapy. The patient was asymptomatic during the follow-up and multiple bone metastases were diagnosed as a result of an increased CA 15.3 marker found. Hormone therapy was the recommended initial treatment with good response and tolerance. Bone lesions remained stabilized for 7 years but after treatment suspension new bone lesions appeared. CA 15.3 marker had increased again. Reintroduction of hormonal therapy achieved again the stabilization of the lesions.
Descritores: Antineoplásicos Hormonais/uso terapêutico
Inibidores da Aromatase/uso terapêutico
Mucina-1/análise
Neoplasias Ósseas/tratamento farmacológico
Neoplasias Ósseas/secundário
Neoplasias da Mama/patologia
-Antineoplásicos/uso terapêutico
Conservadores da Densidade Óssea/uso terapêutico
Biomarcadores Tumorais/análise
Neoplasias da Mama/tratamento farmacológico
Nitrilos/uso terapêutico
Resultado do Tratamento
Tamoxifeno/uso terapêutico
Triazóis/uso terapêutico
Limites: Feminino
Tipo de Publ: Relatos de Casos
Responsável: CL1.1 - Biblioteca Central


  8 / 8 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Id: lil-567061
Autor: Carreño T., Laura; Morales H., Claudia; Elgueta N., Andrea; Leiva C., Nancy.
Título: Enfermedad de Paget mamaria y extramamaria: diagnóstico histopatológico / Mammary and extramammary Paget's disease: histopathologic diagnosis
Fonte: Rev. chil. dermatol;24(2):164-165, 2008. tab.
Idioma: es.
Descritores: Doença de Paget Mamária/patologia
Neoplasias da Mama/patologia
-Antígeno Carcinoembrionário
Diagnóstico Diferencial
Doença de Paget Extramamária/metabolismo
Doença de Paget Extramamária/patologia
Doença de Paget Mamária/metabolismo
Glicoproteínas
Imuno-Histoquímica
Queratinas
Mucina-1
Biomarcadores Tumorais/metabolismo
Neoplasias da Mama/metabolismo
PROTEINAS SACETOLACTATE SYNTHASE
Receptores Estrogênicos
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde